Bioavailability of Curcuminoids From Turmipure Gold® in Different Food Matrices

Summary

The goal of this clinical trial is to learn about the extent to which turmeric compounds in different food matrices becomes available to the body in healthy volunteers. The main question it aims to answer is:

* Is the availability to the body of a turmeric dietary supplement altered when consumed in fruit nectar, oat milk, yogurt drink, or gummies in comparison to a dietary supplement capsule?

Participants will ingest a turmeric dietary supplement as a capsule or in different food matrices on six testing days (separated by at least one week). The day before testing day, a standardized dinner will be provided to the participants in the evening and participants will be instructed to not consume any foods or beverages (except water) and to arrive fasted (12 hours) at the investigation site. Participants will ingest turmeric dietary supplement formulations one by one in random order in the morning of testing days. Regular blood and urine samples will be collected before and up to 24 hours after the turmeric dietary supplement ingestion. Standardized meals will be provided during the entire testing day (lunch, mid-afternoon snack, dinner).

Conditions

• Healthy

Interventions

DIETARY_SUPPLEMENT

TPG capsule

A dietary supplement product in capsule form containing 300 mg Turmipure Gold®

DIETARY_SUPPLEMENT

TPG ready to drink

Ingredient stick containing 300 mg Turmipure Gold® mixed in 60 mL mango fruit nectar

DIETARY_SUPPLEMENT

TPG dairy analog

Ingredient stick containing 300 mg Turmipure Gold® mixed in 240 mL oat milk

DIETARY_SUPPLEMENT

TPG probiotic drink

Ingredient stick containing 300 mg Turmipure Gold® mixed in a 100 mL probiotic yogurt drink base

DIETARY_SUPPLEMENT

TPG gummies

Pectin gummies containing 300 mg Turmipure Gold®

DIETARY_SUPPLEMENT

TPG sport bar

Sport nutrition bar containing 300 mg Turmipure Gold®

Sponsors & Collaborators

• BioFortis

  collaborator OTHER

• Givaudan France Naturals

  lead INDUSTRY

Principal Investigators

• Isabelle Metreau, MD · BioFortis

Study Design

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Model

CROSSOVER

Eligibility

Min Age

18 Years

Max Age

45 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2021-09-14

Primary Completion

2022-05-20

Completion

2022-05-20

Countries

• France

Study Locations